Breaking News Instant updates and real-time market news.

ESPR

Esperion

$23.67

-5.98 (-20.17%)

, AMGN

Amgen

$168.61

-11.5 (-6.39%)

11:10
03/20/17
03/20
11:10
03/20/17
11:10

Esperion LDL-C lowering endpoint news a clear positive, says JPMorgan

After Esperion (ESPR) announced that the FDA confirmed that the bempedoic acid phase 3 program is adequate to support approval of an LDL-C lowering indication prior to outcomes data, JPMorgan analyst Jessica Fye said some expectation for this type of update "started to come into the stock" after Amgen's (AMGN) release of the FOURIER trial top-line results on last Friday. Still, the news is a clear positive for Esperion as it lifts one of the largest overhangs on the stock over the past 18 months. Fye, who now sees the potential for approval of bempedoic acid in 2020, keeps a Neutral rating on Esperion shares.

ESPR

Esperion

$23.67

-5.98 (-20.17%)

AMGN

Amgen

$168.61

-11.5 (-6.39%)

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 28

    Mar

  • 19

    Jul

ESPR Esperion
$23.67

-5.98 (-20.17%)

03/13/17
SBSH
03/13/17
NO CHANGE
Target $39
SBSH
Buy
Esperion selloff Friday a buying opportunity, says Citi
Citi analyst Joel Beatty views Friday's selloff in shares of Esperion Therapeutics as a buying opportunity. Beatty says Reuters' report that President Trump is expected to nominate Scott Gottlieb to lead the FDA is consistent with his Buy thesis on Esperion. The analyst notes that Gottlieb favors deregulation. Beatty keeps a Buy rating on Esperion with a $39 price target.
03/17/17
NEED
03/17/17
NO CHANGE
Target $25
NEED
Strong Buy
Needham calls Esperion selloff on Amgen data 'counter-intuitive'
Needham analyst Chad Messer believes the selloff in shares of Esperion Therapeutics (ESPR) based on Amgen's (AMGN) Repatha's data is "counter-intuitive." The fact that there was a statistically significant benefit confirms that LDL reductions prevent heart attacks and strokes, Messer tells investors in a research note. Bempedoic acid will likely be priced more in line with other oral cholesterol therapies, which makes the value debate for PCSK9 drugs a positive for Esperion, not a negative, the analyst contends. The analyst keeps a Buy rating on Esperion with a $25 price target.
03/20/17
FBCO
03/20/17
UPGRADE
FBCO
Neutral
Esperion upgraded to Neutral from Underperform at Credit Suisse
03/20/17
SBSH
03/20/17
NO CHANGE
Target $39
SBSH
Buy
Esperion likely needs to raise cash before FDA approval, says Citi
Following the company's conference call last night, Citi analyst Joel Beatty continues to believe Esperion Therapeutics' bempedoic acid could be approved by FDA based on LDL lowering as a surrogate endpoint. The company will likely need to raise capital before a potential FDA approval, however, Beatty tells investors in a research note. Further, the FDA is unlikely to provide clarity on LDL as a surrogate ahead of a filing in early 2019, the analyst adds. He keeps a Buy rating on Esperion with a $39 price target. The stock in early trading is up 55%, or $13.03, to $36.70.
AMGN Amgen
$168.61

-11.5 (-6.39%)

03/17/17
OPCO
03/17/17
NO CHANGE
OPCO
Outperform
Amgen oversold on cholesterol data, says Oppenheimer
Oppenheimer analyst Leah Rush Cann says shares of Amgen are oversold after the FOURIER study of Repatha in patients with cardiovascular disease met its key endpoint. The risk reduction grew to 25% after one year on Repatha therapy, which is a "very important result," Cann tells investors in a research note. She believes the current stock price reflects little to no sales of Repatha through 2020. The analyst has an Outperform rating on Amgen, which is trading down 6% to $168.68.
03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
03/17/17
PIPR
03/17/17
NO CHANGE
PIPR
Overweight
Amgen weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer recommends using today's weakness in shares of Amgen as a buying opportunity. The analyst believes Amgen can still turn Repatha into a $5B-plus product and he reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

CXP

Columbia Property

$21.68

-0.27 (-1.23%)

20:50
03/27/17
03/27
20:50
03/27/17
20:50
Upgrade
Columbia Property rating change  »

Columbia Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

SPG

Simon Property

$166.15

-1.8 (-1.07%)

20:45
03/27/17
03/27
20:45
03/27/17
20:45
Conference/Events
Simon Property management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 27

    Apr

HALO

Halozyme

$14.27

0.74 (5.47%)

20:41
03/27/17
03/27
20:41
03/27/17
20:41
Conference/Events
Halozyme management to meet with Canaccord »

Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 01

    Apr

  • 06

    Jun

AYR

Aircastle

$23.44

0.03 (0.13%)

20:38
03/27/17
03/27
20:38
03/27/17
20:38
Conference/Events
Aircastle management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

NEE

NextEra Energy

$131.10

-1.7 (-1.28%)

20:30
03/27/17
03/27
20:30
03/27/17
20:30
Conference/Events
NextEra Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

M

Macy's

$27.93

-0.24 (-0.85%)

20:26
03/27/17
03/27
20:26
03/27/17
20:26
Conference/Events
Macy's management to meet with Guggenheim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

, HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Conference/Events
Heritage Oaks to host special shareholder meeting »

Special Shareholder…

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 15

    May

CCL

Carnival

$58.87

0.27 (0.46%)

, MKC

McCormick

$101.36

0.35 (0.35%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$58.87

0.27 (0.46%)

MKC

McCormick

$101.36

0.35 (0.35%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FDS

FactSet

$174.55

-2.18 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    May

SYY

Sysco

$52.04

-0.77 (-1.46%)

20:17
03/27/17
03/27
20:17
03/27/17
20:17
Conference/Events
Sysco management to meet with Guggenheim »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 20

    Jun

MNK

Mallinckrodt

$44.33

1.24 (2.88%)

20:13
03/27/17
03/27
20:13
03/27/17
20:13
Conference/Events
Mallinckrodt management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 08

    May

OGE

OGE Energy

$35.41

-0.28 (-0.78%)

20:10
03/27/17
03/27
20:10
03/27/17
20:10
Conference/Events
OGE Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

, CMCSK

Comcast

20:03
03/27/17
03/27
20:03
03/27/17
20:03
Periodicals
Comcast to expand streaming video service, Reuters says »

Comcast plans to rebrand…

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$93.17

-0.33 (-0.35%)

20:02
03/27/17
03/27
20:02
03/27/17
20:02
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

FBR

Fibria Celulose

$8.67

-0.22 (-2.47%)

19:58
03/27/17
03/27
19:58
03/27/17
19:58
Conference/Events
Fibria Celulose management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

DXC

DXC Technology

, HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Initiation
DXC Technology, HP Enterprise, CSC initiated at Goldman »

DXC Technology initiated…

DXC

DXC Technology

HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

CSC

CSC

$68.05

0.35 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

TRI

Thomson Reuters

$43.56

-0.19 (-0.43%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Conference/Events
Thomson Reuters management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 28

    Apr

FIS

FIS

$80.41

0.29 (0.36%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Downgrade
FIS rating change at Goldman »

FIS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$24.00

0.12 (0.50%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Conference/Events
Coupa Software management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 06

    Apr

ALK

Alaska Air

$95.00

0.3 (0.32%)

19:44
03/27/17
03/27
19:44
03/27/17
19:44
Conference/Events
Alaska Air management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

  • 04

    May

TIVO

TiVo

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Conference/Events
TiVo management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 10

    May

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

, SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Hot Stocks
Georgia finds 'low pathogenic' bird flu in commercial flock »

The Georgia Department of…

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

PPC

Pilgrim's Pride

$22.31

0.05 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 20

    Jun

KR

Kroger

$28.93

-0.17 (-0.58%)

19:37
03/27/17
03/27
19:37
03/27/17
19:37
Conference/Events
Kroger management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

VALE

Vale

$9.34

0.04 (0.43%)

19:30
03/27/17
03/27
19:30
03/27/17
19:30
Hot Stocks
Vale says Fabio Schvartsman appointed as CEO »

Vale announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSM

Nationstar

$15.05

0.1 (0.67%)

19:21
03/27/17
03/27
19:21
03/27/17
19:21
Initiation
Nationstar initiated at Wedbush »

Nationstar initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNVGY

Lenovo

$12.57

-0.03 (-0.24%)

19:14
03/27/17
03/27
19:14
03/27/17
19:14
Periodicals
Lenovo, Fujitsu postpone PC tie-up, Nikkei says »

Lenovo and Fujitsu will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.